MrBishop
Well-Known Member
SourceIRVINE, Calif., Sept. 20, 2005 (PRIMEZONE) -- "In yet another in what has been a whirlwind of recently reported breakthrough developments, Stemcells Inc. is reporting that researchers in conjunction with the Reeve Irvine Research Center at the University of California, Irvine have restored lost motor function to a mouse with spinal cord injuries using the companies proprietary human stem cells," stated SmallCap Sentinel analyst D.R. Clark. "Mice who had experienced loss of hind leg mobility as a result of crush injuries were able to walk again after the transplant of human neural stem cells, effectively reversing the paralysis according to the study."
Support for the study was also provided by the Christopher Reeve Foundation through its International Research Consortium on Spinal Cord Injury.
Spinal cord injuries is another well-sought after use for stem-cell research.
Brain CancerFDA Approves Brain Stem Cell Transplant and Genentech Inks Another Brain Cancer Deal
City of Industry, CA --(www.FinancialNewsUSA.com)-- 10/24/2005 - Biotechnology industry news provided by Financial News USA (OTC: FNWU) Federal regulators on Thursday approved what would be the first transplant of fetal stem cells into human brains, a procedure that if successful could open the door to treating a host of neural disorders. Stem Cells Inc. (NasdaqNM:STEM), the Palo Alto, Calif. biotechnology company developing the Batten disease treatment, said it receives it fetal tissue from a nonprofit California foundation that also collects tissue from miscarriages and other surgical processes. Stem Cells chief executive Martin McGlynn declined to name the foundation. Geron Corporation (Nasdaq:GERN) will be presenting an update of the company's product development programs on Monday, September 26, 2005, at the UBS Global Life Sciences Conference at 9:30 a.m. Eastern Time in New York City.
Genentech Inc. (NYSENA) signed a deal with a nonprofit foundation in Burlingame to study the use of its colorectal cancer drug Avastin as a treatment for brain cancer. The Food and Drug Administration approved Avastin in February 2004 for colorectal cancer treatment. The drug interferes with angiogenesis, or the growth of blood vessels, in tumors. Genentech has been exploring its use for other types of cancer, including kidney, breast and ovarian. U.S. Biodefense, Inc. (OTCBB: UBDE) and AntiCancer, Inc. announced recently that they have formed a collaboration to research, develop and commercialize novel approaches on utilizing human neural crest stem cell and their potentials in human transplantation.